Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of ... suboptimal response to autologous stem cell transplant. The Cambridge, Mass., company said it expects the move ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

We recently compiled a list of the 10 Best Beaten Down Dividend Stocks to Invest in Now. In this article, we are going to ...

In trading on Monday, shares of Bristol Myers Squibb were yielding above the 5% mark based on its quarterly dividend ...

In the assessment of 12-month price targets, analysts unveil insights for Bristol-Myers Squibb, presenting an average target ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

But I think taken together this year has been a strong year for Bristol-Myers Squibb that sets us up for good momentum in the future and are making very good progress against the Company's strategy.